Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb programme of IPP 204106 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer or pancreatic cancer

Next Previous
Trial Profile

Phase IIb programme of IPP 204106 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer or pancreatic cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IPP 204106 (Primary)
  • Indications Glioblastoma; Malignant melanoma; Pancreatic cancer; Prostate cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use

Most Recent Events

  • 13 Aug 2013 This trial is progressing according to protocol, according to an ImmuPharma media release.
  • 06 Dec 2010 New trial record
  • 19 Nov 2010 ImmuPharma plans to file a US IND for IPP 204106 in the next few months, according to a company media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top